PL2496555T3 - Enancjomer 4R,5S 2-(5-metylo-2-okso-4-fenylo-pirolidyn-1-ylo)acetamidu o aktywności nootropowej - Google Patents

Enancjomer 4R,5S 2-(5-metylo-2-okso-4-fenylo-pirolidyn-1-ylo)acetamidu o aktywności nootropowej

Info

Publication number
PL2496555T3
PL2496555T3 PL10776339T PL10776339T PL2496555T3 PL 2496555 T3 PL2496555 T3 PL 2496555T3 PL 10776339 T PL10776339 T PL 10776339T PL 10776339 T PL10776339 T PL 10776339T PL 2496555 T3 PL2496555 T3 PL 2496555T3
Authority
PL
Poland
Prior art keywords
pyrrolidin
enantiomer
acetamide
oxo
phenyl
Prior art date
Application number
PL10776339T
Other languages
English (en)
Inventor
Ivars Kalvins
Antons Lebedevs
Aleksandrs Cernobrovijs
Maija Dambrova
Liga Zvejniece
Maksims Vorona
Grigorijs Veinbergs
Original Assignee
Grindeks Jsc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grindeks Jsc filed Critical Grindeks Jsc
Publication of PL2496555T3 publication Critical patent/PL2496555T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2632-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/272-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2632-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL10776339T 2009-11-05 2010-11-04 Enancjomer 4R,5S 2-(5-metylo-2-okso-4-fenylo-pirolidyn-1-ylo)acetamidu o aktywności nootropowej PL2496555T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
LVP-09-193A LV14346B (lv) 2009-11-05 2009-11-05 2-(4-Fenil-5-metil-2-oksopirolidin-1-il)-acetamīda 4R,5S-enantiomērs ar nootropo aktivitāti
PCT/EP2010/066767 WO2011054888A1 (en) 2009-11-05 2010-11-04 4r,5s-enantiomer of 2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide with nootropic activity
EP10776339.3A EP2496555B1 (en) 2009-11-05 2010-11-04 4r,5s-enantiomer of 2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide with nootropic activity

Publications (1)

Publication Number Publication Date
PL2496555T3 true PL2496555T3 (pl) 2014-01-31

Family

ID=43466928

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10776339T PL2496555T3 (pl) 2009-11-05 2010-11-04 Enancjomer 4R,5S 2-(5-metylo-2-okso-4-fenylo-pirolidyn-1-ylo)acetamidu o aktywności nootropowej

Country Status (18)

Country Link
US (2) US8791273B2 (pl)
EP (1) EP2496555B1 (pl)
JP (1) JP2013510081A (pl)
CN (1) CN102596905B (pl)
AR (1) AR078904A1 (pl)
CA (1) CA2780040C (pl)
CY (1) CY1114881T1 (pl)
DK (1) DK2496555T3 (pl)
EA (1) EA019890B1 (pl)
ES (1) ES2434024T3 (pl)
HR (1) HRP20131086T1 (pl)
LV (1) LV14346B (pl)
PL (1) PL2496555T3 (pl)
PT (1) PT2496555E (pl)
RS (1) RS53014B (pl)
SI (1) SI2496555T1 (pl)
UA (1) UA107367C2 (pl)
WO (1) WO2011054888A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3127539A1 (en) 2015-08-03 2017-02-08 Latvian Institute Of Organic Synthesis Use of 2-(5s-methyl-2-oxo-4r-phenyl-pyrrolidin-1-yl)-acetamide in the treatment of seizures
RU2711655C1 (ru) * 2019-09-13 2020-01-20 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации Способ крупномасштабного синтеза калиевой соли 2-[2-(2-оксо-4-фенилпирролидин-1-ил)ацетамидо]этансульфокислоты

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2186236B1 (pl) * 1972-05-03 1975-08-01 Logeais Labor Jacques
CN1040747C (zh) * 1994-05-07 1998-11-18 中国科学院昆明植物研究所 N-取代基-4-取代苯基-5-烷基-5-取代苄基吡咯烷酮-2,其中间体,其合成方其法及应用
EP1356812B1 (en) * 2000-12-28 2009-05-13 Hamilton Pharmaceuticals, Inc. Medicines for treatment and prevention of neurogenic pain
ES2340040T3 (es) * 2003-12-24 2010-05-28 Hideki Ohyama Tratamiento para afasia grave en trastorno cerebrovascular de fase cronica.
GB0412019D0 (en) * 2004-05-28 2004-06-30 Novartis Ag Organic compounds
LV13630B (en) 2006-03-16 2007-12-20 Olainfarm As Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone

Also Published As

Publication number Publication date
EA201200536A1 (ru) 2012-09-28
UA107367C2 (xx) 2014-12-25
CN102596905B (zh) 2014-07-16
AR078904A1 (es) 2011-12-14
EA019890B1 (ru) 2014-07-30
LV14346A (lv) 2011-05-20
CA2780040A1 (en) 2011-05-12
EP2496555A1 (en) 2012-09-12
SI2496555T1 (sl) 2013-12-31
CY1114881T1 (el) 2016-12-14
HRP20131086T1 (hr) 2013-12-20
DK2496555T3 (da) 2013-11-11
CN102596905A (zh) 2012-07-18
WO2011054888A1 (en) 2011-05-12
US8791273B2 (en) 2014-07-29
RS53014B (sr) 2014-04-30
PT2496555E (pt) 2013-12-02
EP2496555B1 (en) 2013-08-28
JP2013510081A (ja) 2013-03-21
ES2434024T3 (es) 2013-12-13
US20140296317A1 (en) 2014-10-02
US20120215010A1 (en) 2012-08-23
LV14346B (lv) 2011-07-20
CA2780040C (en) 2014-04-08

Similar Documents

Publication Publication Date Title
IL218078A0 (en) Heterocyclic compounds and uses thereof
IL216973A0 (en) Heterocyclic compounds and their uses
ZA201203137B (en) Substituted benzamide derivatives
GB0901801D0 (en) Improved autoinjector
GB0913385D0 (en) Improved autoinjector
GB0906973D0 (en) Improved autoinjector
ZA201201635B (en) Novel bicyclic urea compounds
EP2438246A4 (en) CONSTRUCTION ASPECTS
IL217183A0 (en) Benzamide derivatives
PL2403379T3 (pl) Układ mocujący
ZA201108502B (en) Processes and intermediates
IL220153A0 (en) Inhibitors of akt activity
PL2493496T3 (pl) Zastosowanie GSTP1
IL214045A (en) A grid made of strips
GB0912103D0 (en) Energy consumption monitor
SI2496555T1 (sl) 4r,5s-enantiomer 2-(5-metil-2-okso-4-fenil-pirolidin-1-il)-acetamida z nootropiäśno aktivnostjo
GB0903740D0 (en) Mrthod for reducing the viscosity of biosolids
ZA201108530B (en) Fastening arrangement
GB0909625D0 (en) Monitors
TWM372743U (en) Improved structure of Kendama
GB0915813D0 (en) Monitoring of,and compensation for vibration
GB2472374B (en) Fastening member
PT2430214T (pt) Ativação de cátodo
TWM390929U (en) Straw set of bottle cap
GB0905280D0 (en) Novel uses of VEGFxxxb